Industry
Biotechnology
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Loading...
Open
2.70
Mkt cap
24M
Volume
61K
High
2.99
P/E Ratio
-0.56
52-wk high
6.75
Low
2.70
Div yield
N/A
52-wk low
2.08
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 1:08 pm
Portfolio Pulse from Avi Kapoor
June 26, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 8:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 8:24 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 7:06 am
Portfolio Pulse from Vandana Singh
May 22, 2024 | 2:55 pm
Portfolio Pulse from Benzinga Insights
May 22, 2024 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.